Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224055 · ClinicalTrials.gov registry record · Phase 4
Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients
A Phase 4 study, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 89
- Enrollment target
NCT00224055 is a Phase 4 study that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 89 participants.
The verdict
NCT00224055, a Phase 4 study, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 89 participants
- Enrollment target
Study Summary
This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cells).
Interventions
- DRUG Ferrous sulfate tablets
- DRUG Sodium Ferric Gluconate Complex in Sucrose Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2003-04 |
| Est. Completion | 2004-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224055
The ClinicalTrials.gov registry entry for NCT00224055 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Ferrous sulfate tablets is the first listed.
NCT00224055 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00224055 about?
NCT00224055 is a clinical study titled "Effect of Ferrlecit® Versus Oral Iron on Iron Deficient Chronic Kidney Disease (CKD) Patients". This study compares the effect of Ferrlecit® (a form of intravenous iron) to ferrous sulfate (a form of oral iron) in treating anemia and iron deficiency in chronic kidney disease patients who are not receiving erythropoietic agents (hormones that stimulate the bone marrow to make more red blood cel...
What is the current status of trial NCT00224055?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 89 participants. The study started on 2003-04. Estimated completion is 2004-09.
What interventions are being tested in trial NCT00224055?
The interventions under investigation include: Ferrous sulfate tablets (DRUG), Sodium Ferric Gluconate Complex in Sucrose Injection (DRUG).
Who is sponsoring clinical trial NCT00224055?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.